Pharmacodynamics

Correct Answer

A — Gi

Rationale

Alpha-2 adrenergic receptors are coupled to Gi, the inhibitory G protein. Gi activation reduces cyclic adenosine monophosphate production by inhibiting adenylyl cyclase, and its released beta-gamma subunits activate inwardly rectifying potassium channels, producing membrane hyperpolarization and reduced sympathetic outflow from the brainstem. Gs stimulates adenylyl cyclase and is coupled to beta-adrenergic receptors. Gq activates phospholipase C and is coupled to alpha-1 adrenergic receptors, muscarinic M1 and M3 receptors, and angiotensin II type 1 receptors. G12 is involved in cytoskeletal signaling and is not a primary effector of adrenergic receptors.

Correct Answer

C — Release of nitric oxide, which activates soluble guanylyl cyclase and raises cyclic guanosine monophosphate

Rationale

Nitroglycerin is an organic nitrate prodrug that undergoes bioactivation in vascular tissue to release nitric oxide. Nitric oxide diffuses into vascular smooth muscle cells and activates soluble guanylyl cyclase, an enzyme that converts guanosine triphosphate to cyclic guanosine monophosphate. Rising cyclic guanosine monophosphate activates protein kinase G, which reduces vascular smooth muscle tone and produces vasodilation. This nitric oxide-cyclic guanosine monophosphate pathway is shared with the mechanism of action of phosphodiesterase 5 inhibitors, which prevent cyclic guanosine monophosphate breakdown — explaining why combining nitroglycerin with sildenafil or tadalafil causes dangerous additive hypotension. Nitroglycerin does not act through Gs, alpha-1 blockade, or phosphodiesterase inhibition directly.

Correct Answer

B — Phosphodiesterase 5 inhibitor

Rationale

Sildenafil inhibits phosphodiesterase type 5, the isoenzyme responsible for degrading cyclic guanosine monophosphate in vascular and penile smooth muscle. By blocking cyclic guanosine monophosphate breakdown, sildenafil prolongs and amplifies the vasodilatory signal initiated by nitric oxide, resulting in smooth muscle relaxation. It does not itself generate nitric oxide or activate guanylyl cyclase — it acts downstream by preserving the second messenger once it has been produced. Soluble guanylyl cyclase activators (such as riociguat) and nitric oxide donors (such as nitroglycerin) act upstream of sildenafil in the same pathway, which is why combining any two agents from this pathway carries a risk of excessive vasodilation and severe hypotension.

Correct Answer

D — Phosphodiesterase 3 inhibitor

Rationale

Milrinone inhibits phosphodiesterase type 3, the isoenzyme responsible for degrading cyclic adenosine monophosphate in cardiac and vascular smooth muscle. By preventing cyclic adenosine monophosphate breakdown, milrinone increases protein kinase A activity, enhancing calcium handling and contractility in the heart (positive inotropy) and promoting relaxation in vascular smooth muscle (vasodilation). Because it acts downstream of beta-adrenergic receptors, milrinone remains effective even when beta receptors are downregulated from chronic heart failure or blocked by beta-blocker therapy. It is sometimes called an inodilator for this reason. Phosphodiesterase 5 inhibitors act on cyclic guanosine monophosphate rather than cyclic adenosine monophosphate and are used primarily for pulmonary arterial hypertension and erectile dysfunction, not acute heart failure inotropy.

Correct Answer

A — Beta-1 adrenergic receptor coupled to Gs

Rationale

Dobutamine acts primarily as a beta-1 adrenergic receptor agonist. Beta-1 receptors are coupled to Gs, the stimulatory G protein, which activates adenylyl cyclase and raises intracellular cyclic adenosine monophosphate. Elevated cyclic adenosine monophosphate activates protein kinase A, which phosphorylates L-type calcium channels and other proteins involved in cardiac excitation-contraction coupling, increasing contractile force. Alpha-1 adrenergic receptors couple to Gq and mediate vasoconstriction, not direct cardiac inotropy in the same pathway. Beta-2 receptors couple to Gs, not Gi. Muscarinic M2 receptors couple to Gi and slow cardiac rate rather than increase contractility.

Correct Answer

C — Alpha-1 adrenergic receptor coupled to Gq

Rationale

Prazosin is a selective alpha-1 adrenergic receptor antagonist. Alpha-1 receptors are coupled to Gq, which activates phospholipase C, generating inositol trisphosphate and diacylglycerol. Inositol trisphosphate releases calcium from intracellular stores, driving vascular smooth muscle contraction and raising blood pressure. Prazosin blocks this pathway, reducing vascular tone and lowering blood pressure. Beta-1 receptors couple to Gs and control cardiac inotropy and chronotropy. Alpha-2 receptors couple to Gi and are the target of clonidine, not prazosin. Muscarinic M3 receptors also couple to Gq but are found in glandular and smooth muscle tissue; prazosin does not act on muscarinic receptors.

Correct Answer

B — Gs activation → adenylyl cyclase → cyclic adenosine monophosphate → protein kinase A → smooth muscle relaxation

Rationale

Beta-2 adrenergic receptors are coupled to Gs. Agonist binding activates Gs, which stimulates adenylyl cyclase to convert adenosine triphosphate to cyclic adenosine monophosphate. Elevated cyclic adenosine monophosphate activates protein kinase A, which phosphorylates myosin light chain kinase and reduces its activity, lowering the phosphorylation state of myosin and promoting smooth muscle relaxation and bronchodilation. The Gq pathway activates phospholipase C and raises intracellular calcium — the opposite effect, promoting smooth muscle contraction rather than relaxation. The Gi pathway inhibits adenylyl cyclase and reduces cyclic adenosine monophosphate, which in smooth muscle would favor contraction rather than relaxation.

Correct Answer

D — Activation of Gi → inhibition of adenylyl cyclase → reduced cyclic adenosine monophosphate → decreased neuronal excitability

Rationale

Mu-opioid receptors are coupled to Gi, the inhibitory G protein. When morphine or other opioid agonists bind, Gi is activated and its alpha subunit inhibits adenylyl cyclase, reducing intracellular cyclic adenosine monophosphate. The beta-gamma subunit released from activated Gi also opens inwardly rectifying potassium channels, hyperpolarizing the neuron, and inhibits voltage-gated calcium channels, reducing neurotransmitter release at presynaptic terminals. The net effect is reduced neuronal excitability and attenuated pain signal transmission. This Gi-mediated reduction in cyclic adenosine monophosphate is clinically significant: chronic opioid exposure leads to compensatory upregulation of adenylyl cyclase, and when opioids are withdrawn the overexpressed enzyme produces a cyclic adenosine monophosphate surge that drives the autonomic symptoms of opioid withdrawal.

Correct Answer

A — Gq → phospholipase C → inositol trisphosphate → calcium release from endoplasmic reticulum → contraction

Rationale

Alpha-1 adrenergic receptors are coupled to Gq. When activated, Gq stimulates phospholipase C-beta, which cleaves membrane phosphatidylinositol 4,5-bisphosphate into two second messengers: inositol trisphosphate and diacylglycerol. Inositol trisphosphate travels to the endoplasmic reticulum and triggers calcium release into the cytoplasm, raising intracellular free calcium. This calcium surge activates calmodulin-dependent myosin light chain kinase, phosphorylating myosin and driving smooth muscle contraction and vasoconstriction. Drugs that block alpha-1 receptors — such as prazosin, doxazosin, and terazosin — interrupt this pathway and lower blood pressure. The Gs and Gi pathways act through cyclic adenosine monophosphate, not through calcium-mediated smooth muscle contraction.

Correct Answer

C — Nitroglycerin raises cyclic guanosine monophosphate by donating nitric oxide, and sildenafil prevents cyclic guanosine monophosphate breakdown — both drugs amplify the same vasodilatory second messenger

Rationale

Nitroglycerin is bioactivated to nitric oxide, which activates soluble guanylyl cyclase in vascular smooth muscle, raising cyclic guanosine monophosphate and producing vasodilation. Sildenafil inhibits phosphodiesterase type 5, the enzyme responsible for degrading cyclic guanosine monophosphate in the same cells. When both drugs are present, nitroglycerin increases cyclic guanosine monophosphate production while sildenafil simultaneously prevents its breakdown, producing a far greater rise in cyclic guanosine monophosphate than either drug alone. The resulting vasodilation can cause severe, potentially fatal hypotension. This is a pharmacodynamic interaction at the level of the same second messenger in the same cell — not a pharmacokinetic interaction involving drug metabolism.

Correct Answer

B — G protein-coupled receptor kinases phosphorylate the activated receptor, creating docking sites for beta-arrestin, which sterically uncouples the receptor from Gs

Rationale

Rapid receptor desensitization begins within seconds to minutes of sustained agonist binding. G protein-coupled receptor kinases specifically phosphorylate serine and threonine residues on the intracellular domains of agonist-occupied receptors. This phosphorylation creates high-affinity binding sites for beta-arrestin proteins, which bind and physically block the receptor's ability to interact with its G protein. The receptor remains at the cell surface but can no longer activate Gs efficiently, attenuating the cyclic adenosine monophosphate signal despite continued agonist presence. This is the molecular basis for the waning bronchodilatory response seen with continuous beta-agonist exposure. Receptor degradation in lysosomes occurs later, over hours, and represents downregulation rather than desensitization. Adenylyl cyclase is not directly inactivated by cyclic adenosine monophosphate.

Correct Answer

D — Continuous nitrate exposure depletes the vascular thiol groups needed for nitric oxide generation and suppresses soluble guanylyl cyclase activity; managed by a daily nitrate-free interval of 8 to 12 hours

Rationale

Nitrate tolerance, a form of tachyphylaxis, develops within 24 hours of continuous organic nitrate exposure. The predominant mechanisms involve depletion of vascular sulfhydryl (thiol) groups required for bioactivation of nitroglycerin to nitric oxide, and suppression of soluble guanylyl cyclase activity. Without adequate nitric oxide production or responsive guanylyl cyclase, cyclic guanosine monophosphate does not rise sufficiently, and the vasodilatory response is lost. The clinical solution is a nitrate-free interval of 8 to 12 hours daily — typically overnight when anginal risk is lowest and the patient is recumbent — allowing the nitric oxide pathway to recover before the next day's dosing period. Increasing the dose does not restore effectiveness once tolerance has developed through this mechanism.

Correct Answer

A — Chronic beta-1 receptor blockade causes receptor upregulation; abrupt discontinuation exposes the enlarged receptor population to ambient catecholamines, producing rebound tachycardia and increased myocardial oxygen demand

Rationale

During chronic beta-blocker therapy, the sustained reduction in receptor signaling prompts the cell to compensate by increasing beta-1 receptor number and coupling efficiency — receptor upregulation. While the drug is present, this upregulation is clinically silent because the new receptors are also blocked. When the beta-blocker is stopped abruptly, the enlarged, hypersensitive receptor population encounters normal circulating catecholamine concentrations and generates a supra-normal adrenergic response. In patients with coronary artery disease, the resulting rebound tachycardia and increased myocardial oxygen demand can precipitate unstable angina, myocardial infarction, or ventricular arrhythmias. Beta-blockers should be tapered gradually over one to two weeks when discontinuation is necessary in these patients.

Correct Answer

C — Chronic opioid-mediated Gi activation caused compensatory upregulation of adenylyl cyclase; withdrawal removes the inhibition and the overexpressed enzyme produces a cyclic adenosine monophosphate surge driving autonomic hyperexcitability

Rationale

During chronic opioid use, sustained Gi-mediated inhibition of adenylyl cyclase causes neurons — particularly in the locus coeruleus — to compensate by synthesizing more adenylyl cyclase. The cell adapts to the suppressed cyclic adenosine monophosphate environment by upregulating the enzyme responsible for making it. When opioids are abruptly withdrawn, the Gi-mediated inhibition is suddenly removed, and the overexpressed adenylyl cyclase is now unopposed. The resulting cyclic adenosine monophosphate surge produces neuronal hyperexcitability and the autonomic storm of opioid withdrawal: tachycardia, hypertension, lacrimation, rhinorrhea, piloerection, diarrhea, and intense dysphoria. This explains why clonidine — an alpha-2 agonist that also signals through Gi — partially suppresses opioid withdrawal symptoms by independently reducing cyclic adenosine monophosphate in the same neurons.

Correct Answer

D — Tachyphylaxis has developed through depletion of vascular thiol groups and suppression of soluble guanylyl cyclase; a daily 8 to 12 hour nitrate-free interval will allow the pathway to recover and restore effectiveness

Rationale

Continuous organic nitrate exposure produces tachyphylaxis — rapid tolerance that develops within 24 hours of uninterrupted use. The mechanism involves depletion of the vascular sulfhydryl groups required for nitric oxide generation from the drug, along with suppression of soluble guanylyl cyclase responsiveness. Because the cyclic guanosine monophosphate pathway cannot be fully activated, vasodilation is reduced. The established clinical solution is a daily nitrate-free interval of 8 to 12 hours, typically overnight when hemodynamic demand is lowest. This period allows thiol group replenishment and restoration of guanylyl cyclase sensitivity, so the drug is again effective during the active portion of the day. The tolerance is reversible with drug-free intervals — it does not represent permanent receptor loss.

Correct Answer

A — Chronic beta-1 blockade caused receptor upregulation; without the drug, upregulated receptors are exposed to circulating catecholamines, producing rebound tachycardia and increased myocardial oxygen demand

Rationale

Chronic beta-adrenergic receptor blockade signals to cardiac cells that sympathetic input is reduced, and they compensate by increasing the number and sensitivity of beta-1 receptors — receptor upregulation. While metoprolol is present, these extra receptors are blocked and the patient is clinically stable. When the drug is stopped abruptly, circulating epinephrine and norepinephrine bind the enlarged receptor population and produce a supra-normal adrenergic response: rebound tachycardia, hypertension, and increased myocardial oxygen demand. In a patient with coronary artery disease whose blood supply cannot match the demand, this triggers ischemia. Beta-blockers should be continued through the perioperative period or tapered gradually, not stopped abruptly, in patients with coronary artery disease.

Correct Answer

B — Clonidine activates alpha-2 receptors coupled to Gi in locus coeruleus neurons, independently reducing cyclic adenosine monophosphate and suppressing the noradrenergic hyperactivity driving withdrawal symptoms

Rationale

During opioid withdrawal, the previously opioid-suppressed locus coeruleus fires at an elevated rate driven by the cyclic adenosine monophosphate surge from upregulated adenylyl cyclase. This noradrenergic hyperactivity produces the autonomic symptoms of withdrawal. Clonidine is an alpha-2 adrenergic agonist whose receptors are coupled to Gi. By activating Gi independently of opioid receptors, clonidine inhibits adenylyl cyclase and reduces cyclic adenosine monophosphate in the same locus coeruleus neurons, dampening their hyperactivity without requiring mu-opioid receptor activation. Clonidine does not bind opioid receptors, does not directly inhibit adenylyl cyclase as an enzyme, and does not signal through Gq. It provides symptomatic relief of the autonomic component of withdrawal but does not address the craving or dysphoria driven by mesolimbic reward pathway changes.

Correct Answer

C — Chronic supraphysiological glucocorticoid exposure suppressed the hypothalamic-pituitary-adrenal axis; the adrenal cortex has atrophied and cannot produce cortisol in response to physiological stress

Rationale

Exogenous glucocorticoids suppress the hypothalamic-pituitary-adrenal axis through negative feedback at glucocorticoid receptors in the hypothalamus and pituitary, reducing secretion of corticotropin-releasing hormone and adrenocorticotropic hormone. Without adrenocorticotropic hormone stimulation, the adrenal cortex gradually atrophies and loses its capacity for cortisol synthesis. After six weeks of high-dose prednisone, the patient's adrenal cortex cannot mount an adequate cortisol response to physiological stress — infection, hypotension, or illness — which are situations that normally require a several-fold increase in cortisol output. Abrupt discontinuation leaves the patient with neither exogenous steroid nor functional endogenous production, precipitating adrenal insufficiency. The management is to taper glucocorticoids slowly and to provide stress-dose supplementation during any significant physiological challenge in patients who have received prolonged treatment.